J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

President Donald Trump has nominated Robert F. Kennedy Jr., an environmental lawyer with no formal medical or public health expertise, as secretary of Health and Human Sciences.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.